Eosinophilic Gastritis: Dupilumab Treatment Study

We are investigating how well dupilumab works for adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. The study will also look at the safety and side effects of this treatment.

1-2 years Efficacy phase (II)Post-Trial Drug Access Partially Remote Standard Medicines InjectionGastroenterologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Dupixent

Dupixent is a medicine used to treat eczema and certain asthma symptoms.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dupilumab

Dupilumab is a substance that reduces allergic inflammation to treat moderate-to-severe eczema, some asthma, and nasal polyps.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Assistance Publique Hopitaux De Paris

Département d’hépatologie

Clichy, France

Centre Hospitalier Universitaire De Toulouse

Département hépato-gastroentérologie

Ramonville-Saint-Agne, France

University Hospital Consorziale Policlinico

UOC Di Ematologia

Altamura, Italy

Sponsor: Regeneron Pharmaceuticals Inc.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.